Search Icon
SideMenu
Home
Blog

Blog
  • Blog

The IRA Hurts Generic and Biosimilar Medication Competition
  • Blog

Access! 2025 Recap: A Call to Action for the Future of Generics and Biosimilars
  • Blog

Your All ACCESS! Pass
  • Blog

Redesigned Medicare Drug Program Still Allows PBMs to Deny Patients Access to Lower-Cost Generics & Biosimilars
  • Blog

Congress Should Pass Legislation to End the Shenanigans That Allow Brand-Name Drug Manufacturers to Delay Generic Competition and Charge Higher Prices for Longer Periods
  • Blog

GRx+Biosims 2024 Conference Recap
  • Blog

Want to Save Patients Money on Medicine? No Need to Reinvent the Wheel
  • Blog

Senate Finance Committee Bill Addressing Drug Shortages Would Provide Long Overdue Relief from Penalties Hurting Generic Drug Market
  • Blog

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
  • Blog

Access! 2024 – Charting a Sustainable Path for Generics and Biosimilars
  • Blog

2023 Report
  • Blog

GRx+Biosims 2023 Conference Recap
Load More
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington DC 20001
JOIN

Advocacy

About Us

Events

Resources

Sign-up for Update

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Subscribe

© 2025 Association for Accessible Medicines (AAM), All Rights Reserved
Privacy Policy  |  Terms of Use  |  Contact

Stay Connected

For the latest updates, follow us on social media.

Facebook-f X-twitter Linkedin-in Youtube Instagram